Related Experiment Video

Updated: Jun 11, 2025

Post-Myocardial Infarction Heart Failure in Closed-chest Coronary Occlusion/Reperfusion Model in Göttingen Minipigs and Landrace Pigs
14:35

Post-Myocardial Infarction Heart Failure in Closed-chest Coronary Occlusion/Reperfusion Model in Göttingen Minipigs and Landrace Pigs

Published on: April 17, 2021

8.5K

Colchicine effect on biomarkers of cardiac remodelling and atherosclerosis in ST-elevation myocardial infarction: A

Hanan Ahmed Hassanain1, Lamia Mohamed El Wakeel2, Hazem Khorshid3

  • 1Ain Shams University Specialized Hospital, Cairo, Egypt.

British Journal of Clinical Pharmacology
|October 3, 2024
PubMed

Insights

Colchicine shows promise in reducing triglyceride levels and the triglyceride/HDL-C ratio in ST-elevation myocardial infarction (STEMI) patients. This anti-inflammatory drug was well-tolerated and may impact atherosclerosis and cardiac remodelling post-STEMI.

Area of Science:

  • Cardiology
  • Inflammation Research
  • Atherosclerosis Studies

Background:

  • Atherosclerotic cardiovascular disease, driven by inflammation, is a leading cause of mortality.
  • ST-elevation myocardial infarction (STEMI) carries a high risk of subsequent cardiovascular events and mortality.
  • Investigating novel therapeutic targets for post-STEMI management is crucial.

Purpose of the Study:

  • To evaluate the efficacy of colchicine in mitigating inflammation, cardiac remodelling, and atherosclerotic risk factors in STEMI patients.
  • To assess colchicine's impact on specific biomarkers including sST2, interleukin-1β, lipid profiles, and left ventricular ejection fraction.

Main Methods:

  • A randomized controlled trial involving 88 STEMI patients post-percutaneous coronary intervention.
  • Patients received either standard care or standard care plus 0.5 mg colchicine twice daily for 3 months.
  • Key parameters were measured at baseline and after 3 months of treatment.

Main Results:

  • Colchicine significantly reduced triglyceride (TG) levels and the TG/high-density lipoprotein cholesterol (HDL-C) ratio.
  • No significant changes were observed in sST2, interleukin-1β levels, or left ventricular ejection fraction.
  • sST2 levels positively correlated with TG/HDL-C ratio at follow-up.

Conclusions:

  • Colchicine demonstrates a beneficial effect on lipid metabolism, specifically reducing TG and TG/HDL-C ratio in STEMI patients.
  • The drug was found to be safe and well-tolerated in this patient cohort.
  • Larger, long-term studies are warranted to confirm colchicine's clinical impact on cardiac remodelling outcomes post-STEMI.
Abstract

Keywords:
ST‐elevation myocardial infarctioncardiac remodellingcolchicineinterleukin‐1βsoluble suppressor of tumorigenicitytriglyceride/high‐density lipoprotein ratiotriglycerides

More Related Videos

Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty10:03

Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty

Published on: January 28, 2020

5.2K
Tissue Preparation Techniques for Contrast-Enhanced Micro Computed Tomography Imaging of Large Mammalian Cardiac Models with Chronic Disease12:15

Tissue Preparation Techniques for Contrast-Enhanced Micro Computed Tomography Imaging of Large Mammalian Cardiac Models with Chronic Disease

Published on: February 8, 2022

2.5K

Related Concept Videos

Blood Studies for Cardiovascular System I: Cardiac Biomarkers01:20

Blood Studies for Cardiovascular System I: Cardiac Biomarkers

Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
109
Myocarditis III: Medical Management01:14

Myocarditis III: Medical Management

Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
2
Acute Coronary Syndrome III: Diagnostic studies01:30

Acute Coronary Syndrome III: Diagnostic studies

Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
3
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
63
Myocarditis II: Clinical features and Diagnostic Tests01:27

Myocarditis II: Clinical features and Diagnostic Tests

Myocarditis is an inflammation of the heart muscle. The symptoms vary widely, encompassing asymptomatic presentations to severe, acute manifestations.Clinical PresentationAsymptomatic cases: In some instances, myocarditis may be asymptomatic, with the infection resolving without intervention. These cases often go undetected unless discovered incidentally through diagnostic imaging or tests conducted for other reasons.General Early Symptoms: Early symptoms of myocarditis are non-specific and can...
2
Acute Coronary Syndrome II: Pathophysiology and clinical manifestations01:19

Acute Coronary Syndrome II: Pathophysiology and clinical manifestations

Acute Coronary Syndrome (ACS) encompasses a spectrum of heart conditions caused by sudden obstruction of coronary arteries, typically resulting from the rupture of an atherosclerotic plaque and subsequent thrombus (blood clot) formation. This obstruction can lead to partial or complete blockage of blood flow, causing varying degrees of myocardial ischemia or infarction.ACS includes the following clinical entities:Unstable Angina (UA)Non-ST-Elevation Myocardial Infarction (NSTEMI)ST-Elevation...
3